D. pteronyssinus Dust Mite SCIT: The Molecular Biology Behind HDM Shots
Dermatophagoides pteronyssinus (European house dust mite) SCIT uses FDA-standardized 10,000 AU/mL extract targeting 7–12 µg Der p 1 at maintenance. Der p 1 simultaneously breaches epithelial barriers, amplifies IgE (CD23 cleavage), suppresses Treg (CD25 cleavage), and activates PAR-2; Der p 2 substitutes for MD-2 in the TLR4 complex (Trompette 2009 Nature). Der p 23 predicts childhood-onset asthma and is missed by extract-based diagnostics in 4–5% of sensitized patients.
D. pteronyssinus (European House Dust Mite) Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to d. pteronyssinus (european house dust mite) — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of d. pteronyssinus (european house dust mite) allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of d. pteronyssinus (european house dust mite) immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of d. pteronyssinus (european house dust mite) extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for d. pteronyssinus (european house dust mite) allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing d. pteronyssinus (european house dust mite) extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription d. pteronyssinus (european house dust mite) immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat d. pteronyssinus (european house dust mite) allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is D. pteronyssinus (European House Dust Mite)?
The biology, taxonomy, and clinical fingerprint of D. pteronyssinus (European House Dust Mite) — the foundation of how SCIT targets it.
Dermatophagoides pteronyssinus: Der p 1 cleaves tight junction proteins occludin, claudin-1, and ZO-1; Der p 2 substitutes for MD-2 in the TLR4 complex; Der p 23 coats fecal pellet peritrophic membranes and predicts childhood asthma.
- Scientific name
- Dermatophagoides pteronyssinus
- Family
- PyroglyphidaeHouse dust mite family
- Type
- Indoor dust mite — perennial aeroallergen via fecal pellets in bedding, carpets, and upholstery
- Native to
- Coastal and humid temperate environments worldwide; dominant species in the eastern US coastal states, Europe, and humid tropics
- Allergen proteins
- Der p 1 (cysteine protease, 24–25 kDa, 70–100% IgE reactivity) — major allergen; the most studied single allergen in allergy medicine (major)Der p 2 (NPC2/MD-2 homolog, 14 kDa, 80–100% IgE reactivity) — major allergen; auto-adjuvant TLR4 activity (major)Der p 23 (peritrophin-like, 8 kDa, 42–74% IgE reactivity) — major allergen; predicts childhood-onset asthma; absent from 13 of tested commercial extracts (major)Der p 10 (tropomyosin, 36–37 kDa, 5–18%) — pan-allergen cross-reacting with shrimp Pen a 1 and cockroach Bla g 7Der p 11 (paramyosin, 103 kDa, ~10% general / >50% in atopic dermatitis) — major in atopic dermatitis specifically39 allergen groups recognized through Der p 39
- Particle size
- 10–40 μm (fecal pellets carrying Der p 23 in peritrophic membrane); >95% of mite allergen is fecal-pellet-associated
- Avoidance difficulty
- Nearly impossible
How D. pteronyssinus (European House Dust Mite) Allergy Presents
Symptoms by body system — useful for distinguishing D. pteronyssinus (European House Dust Mite) sensitivity from overlapping allergies and infections.
Respiratory
- Perennial allergic rhinitis: nasal congestion, sneezing, and rhinorrhea year-round with autumn peak
- Asthma — Der p 2's TLR4 auto-adjuvant activity drives innate immune amplification; Sporik 1990 NEJM established the 10 µg Der p 1/g threshold for acute asthma risk
- Chronic rhinosinusitis in patients with perennial uncontrolled HDM disease
- Nocturnal wheezing and coughing from concentrated mite allergen in mattresses and pillows
- Der p 23 IgE at age ≤5 independently predicts school-age asthma development (Resch 2015 JACI)
Ocular
- Perennial allergic conjunctivitis with itching and watering — characteristic of year-round HDM sensitization
- Eye symptoms worst in autumn as mite populations peak post-summer
- Allergic shiners (periorbital darkening and edema) from chronic rubbing and inflammation
Dermal
- Atopic dermatitis flares — Der p 11 (paramyosin, 103 kDa) sensitizes >50% of atopic dermatitis patients but only ~10% of rhinitis-only patients
- Eczema exacerbation with increased indoor humidity that drives mite proliferation
- Urticaria from direct mite exposure (uncommon but documented)
Systemic
- Fatigue and sleep disruption from nocturnal respiratory symptoms and poor asthma control
- Reduced school and work performance from perennial uncontrolled rhinitis
- Shellfish allergy in Der p 10-sensitized patients via tropomyosin cross-reactivity with shrimp Pen a 1 (81% identity) and cockroach Bla g 7
Der p 23 is the allergen that changed how I think about dust mite diagnostics in children. It sensitizes 74% of HDM-allergic patients but is absent from 13 tested commercial extract products — meaning children with monosensitization to Der p 23 get a 'negative' dust mite test and never receive SCIT. When I see a child with asthma and weak or negative Der p 1/2 results, Der p 23 is the next molecule I test.
Where D. pteronyssinus (European House Dust Mite) Triggers Year-Round
D. pteronyssinus (European House Dust Mite) is a perennial trigger — exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundPerennial — D. pteronyssinus peaks in autumn in coastal humid regions; nocturnal symptoms characteristic year-round· Year-round with autumn peak; highest concentrations in bedroom bedding
US Exposure Map
21 high-intensity statesWhat D. pteronyssinus (European House Dust Mite) Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
D. pteronyssinus shares ~85% IgE cross-reactivity with D. farinae via highly conserved Group 1 (cysteine protease) and Group 2 (NPC2/MD-2) allergen families; Der p 10 (tropomyosin) creates the pan-allergen bridge to shellfish and cockroach.
Standard US dual-species vial targeting 7–12 µg Der p 1 + 7–12 µg Der f 1 per injection
Der p 1 / Der f 1 share ~80% sequence identity; Der p 2 / Der f 2 share ~87–88%; Group 10 shares ~95%
Mite-Shellfish Cross-Reactivity via Der p 10
Der p 10 (tropomyosin, 36–37 kDa) shares 81% sequence identity with shrimp Pen a 1 and ~80% with cockroach Bla g 7. Over 70% of HDM-allergic patients show IgE to shrimp in some studies, with 55% reacting to shrimp tropomyosin specifically. Der p 10-specific IgE is the key biomarker for predicting clinical shellfish reactivity in dust-mite-allergic patients.
Is SCIT Right for Your D. pteronyssinus (European House Dust Mite) Allergy?
Answer 5 questions to assess whether D. pteronyssinus allergy shots are right for your year-round symptoms.
How severe are your dust mite allergy symptoms?
The D. pteronyssinus (European House Dust Mite) SCIT Protocol
D. pteronyssinus SCIT uses FDA-standardized 10,000 AU/mL extract; maintenance targets 7–12 µg Der p 1 per injection per AAAAI/ACAAI Practice Parameters, reached over 3–6 months of weekly build-up.
Starting at maximum dilution (1:10,000), the Der p 1 dose is escalated weekly toward the target maintenance concentration. A mandatory 30-minute post-injection observation period applies at every visit. Patients with poorly controlled asthma (FEV1 <70% predicted) should not receive injections on that day. Cluster build-up protocols (4–8 weeks) are available at selected centers with enhanced monitoring.
Monthly injections maintain immune tolerance at target Der p 1 dose. Benefits typically accumulate over the first 1–2 years of maintenance; PAT study showed lasting benefits 7 years after 3-year treatment. Component-resolved monitoring of Der p 23 may identify patients requiring supplementation with recombinant Der p 23 if monosensitization is identified.
Disease modification from 3–5 years of SCIT produces durable immunologic changes — reduced IgE, increased IgG4, Th1/Treg polarization — that typically persist years after stopping. Most allergists recommend 3–5 years before considering discontinuation.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for D. pteronyssinus (European House Dust Mite) SCIT
D. pteronyssinus SCIT is backed by the same landmark evidence base as D. farinae SCIT — they share the same extract pool and primary efficacy trials — with additional molecular evidence from the ODACTRA pivotal trials.
- HDM SCIT symptom score SMD vs placebo85%Kim JM et al. 2021, JACI Practice 9:4450 — network meta-analysis of 26 RCTs: SMD -1.669 (95% CI -2.7 to -0.639)
- Asthma exacerbation reduction (HDM SLIT-tablet asthma trial P014)33%Asthma trial P014, 834 European adults — 31–34% risk reduction; 42% vs 15% ICS reduction
- Pediatric TCRS reduction (MT-12 trial, ODACTRA)22%Nolte H et al. MT-12 trial, 1,460 children ages 5–11 — 22.0% relative reduction (95% CI 12.0–31.1, P<0.0001)
- Der p 23 IgE predicting asthma at school age (childhood cohort)74%Resch Y et al. 2015, JACI 136:1083 — Der p 23 IgE at age ≤5 predicted school-age asthma; 74% IgE reactivity
D. pteronyssinus SCIT produces the largest symptom-score improvement across all allergen immunotherapy modalities (Kim 2021). Der p 1's four-front immune attack (barrier disruption, IgE amplification, Treg suppression, innate activation), Der p 2's TLR4 auto-adjuvant mechanism (Trompette 2009 Nature), and Der p 23's pediatric asthma prediction role (Resch 2015) together explain why Dermatophagoides allergy is particularly amenable to immunotherapy-mediated disease modification.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
D. pteronyssinus (European House Dust Mite) SCIT Side Effects
D. pteronyssinus SCIT has one of the best-characterized safety profiles in allergy practice due to decades of experience with FDA-standardized extract.
Local reactions
4 documentedSystemic reactions
4 documentedD. pteronyssinus SCIT has been administered for decades with an excellent safety record when standard protocols are followed. Poorly controlled asthma is the most important contraindication — FEV1 must be ≥70% predicted before each injection. Curex carries that record into at-home care: your first dose and every dose change are supervised live over Zoom, a prescribed epinephrine auto-injector is confirmed on hand, and a board-certified allergist oversees gradual, week-by-week dose escalation. (The ODACTRA SLIT-tablet is a separate FDA-approved option whose first dose is taken in-office with 30-minute observation.)
SCIT vs Alternatives for D. pteronyssinus (European House Dust Mite)
D. pteronyssinus-sensitized patients have four well-characterized options: SCIT (strongest efficacy evidence), ODACTRA SLIT-tablet (FDA-approved at-home alternative), environmental control, and pharmacotherapy.
| Criterion | At-home SCIT (Curex)Best | ODACTRA SLIT-tablet | Avoidance measures | Medications |
|---|---|---|---|---|
| Effectiveness | Excellent — SMD -1.669, largest in allergen IT literature | Good — 17–22% TCRS improvement; 31–34% asthma exacerbation reduction | Modest alone; significant when multicomponent (WAO 2024: RR 3.39) | Good for symptom suppression; no disease modification |
| 5-yr cost | $3,500–$12,000 over 5 years | Moderate — no office visit costs but tablet price varies | Low — $50–$300 one-time for encasings | $500–$2,000/yr ongoing |
| Duration | 3–5 years weekly then monthly injections | 3–5 years daily sublingual tablet | Ongoing — must be maintained indefinitely | Indefinite daily use |
| Convenience | At-home weekly self-injection with Curex; no clinic visits | Home-based daily after first in-office dose | Minimal lifestyle disruption | Daily pills and nasal sprays |
| Safety | USP <797> serum; Zoom-supervised first/changed dose; epinephrine Rx on hand | Black-box warning; epinephrine Rx required | No treatment risks | Generally safe |
| Lasting effect | Disease-modifying; 7+ years lasting benefit | Disease modification documented | Effective only while maintained | No lasting effect after stopping |
At-home SCIT (Curex)Best
ODACTRA SLIT-tablet
Avoidance measures
Medications
For patients with confirmed D. pteronyssinus sensitization and inadequate pharmacotherapy response, SCIT is the most evidence-supported path to lasting disease modification. Curex's at-home blood testing panel includes Der p 1, Der p 2, and Der p 23 components individually — critical because Der p 23 is underrepresented in most commercial extracts and independently predicts pediatric asthma. Curex now delivers that same subcutaneous immunotherapy as an at-home allergy shot at $129/month: a personalized Dermatophagoides serum compounded under USP <797>, with your first injection and every dose change supervised live over Zoom by the prescribing physician, a prescribed epinephrine auto-injector confirmed on hand, and week-by-week dose escalation — so eligible patients get the disease-modifying modality without weekly clinic visits.
What D. pteronyssinus (European House Dust Mite) SCIT Actually Costs
Most major US insurers cover D. pteronyssinus SCIT under standard allergy benefits when ordered by a board-certified allergist with supporting diagnostic testing. ODACTRA SLIT-tablet coverage varies by plan and requires prior authorization. Out-of-pocket cost depends on deductible and co-insurance; verify with your insurer before starting.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your d. pteronyssinus (european house dust mite) allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
D. pteronyssinus (European House Dust Mite) SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Der p 23 is the third major allergen of D. pteronyssinus — a small (8 kDa) peritrophin-like protein found in the peritrophic membrane lining mite fecal pellets. Despite being present in tiny quantities (30-fold less mRNA expression than Der p 1), it elicits IgE in 74% of HDM-allergic patients (Weghofer 2013 J Immunol). Critically, approximately 4–5% of Der p 23-sensitized patients are monosensitized — they have IgE to Der p 23 but not to Der p 1 or Der p 2. Because Der p 23 is absent from 13 tested commercial HDM extract products, standard extract-based skin testing misses these patients entirely, leaving them with untreated asthma-predisposing sensitization. Resch 2015 JACI showed that Der p 23 IgE at age ≤5 predicts school-age asthma development — making component-resolved testing for Der p 23 essential in any child with asthma and suspected HDM sensitization.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.